New hope for kids with rare MMA: B12 shot trial launches
NCT ID NCT07163364
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times
Summary
This study tests a vitamin B12 injection (hydroxocobalamin) in 20 children aged 6 months to 18 years with a rare genetic condition called methylmalonic acidemia (MMA) with high homocysteine. The goal is to see if the injection can normalize acid levels in the blood or urine and improve other health markers. Participants will receive the drug as maintenance therapy, and the study is open-label (everyone knows they are getting the treatment).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHYLMALONIC ACIDEMIA (MMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.